Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus WIXELA INHUB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus WIXELA INHUB.
ASMANEX HFA vs WIXELA INHUB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Wixela Inhub is an inhaled corticosteroid (fluticasone propionate) and long-acting beta2-adrenergic agonist (salmeterol) combination. Fluticasone propionate reduces inflammation by binding to glucocorticoid receptors, inhibiting pro-inflammatory mediators. Salmeterol stimulates beta2-receptors in bronchial smooth muscle, leading to bronchodilation via activation of adenylate cyclase and increased cAMP.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
2 inhalations (total dose 50 mcg indacaterol/110 mcg glycopyrrolate) once daily via oral inhalation.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged (up to 30-50 hours) in renal impairment.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily renal excretion (70-80%) as unchanged drug; biliary/fecal (20-30%) as parent and metabolites.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid/LABA Combination